We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Financial Incentives and Cholesterol Levels—Reply

Andrea B. Troxel, ScD1; David A. Asch, MD1; Kevin G. Volpp, MD, PhD1
[+] Author Affiliations
1University of Pennsylvania, Philadelphia
JAMA. 2016;315(15):1658. doi:10.1001/jama.2016.0315.
Text Size: A A A
Published online


In Reply Drs Lesser and McCormack note limitations to relying on LDL-C measurement as an intermediate end point to assess what physicians really want to improve, which is cardiovascular risk.

Despite known limitations, LDL-C targets offered important advantages in our trial. First, when the trial was initiated, LDL-C targets were a dominant clinical guideline. Second, targets are intuitively appealing to patients and clinicians, and the lack of targets in current guidelines may pose challenges to motivating adherent behaviors. Third, although quarterly LDL-C assessments might be more variable than desired, their perceived validity may be more important than their actual validity when considering patient adherence and adoption of healthier behaviors. Although financial incentives could motivate inappropriate patient behavior (eg, pretending to take medications), awareness of quarterly measurement of the outcome likely mitigates adoption of such behaviors. Even if quarterly LDL-C measurements are noisy, they might discourage gaming behavior to the extent that participants believe they are accurate.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




April 19, 2016
Lenard I. Lesser, MD, MSHS; James P. McCormack, PharmD
1Palo Alto Medical Foundation Research Institute, Palo Alto, California
2Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
JAMA. 2016;315(15):1657-1658. doi:10.1001/jama.2016.0309.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...